These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8702653)

  • 1. An activating mutation in the ATP binding site of the ABL kinase domain.
    Allen PB; Wiedemann LM
    J Biol Chem; 1996 Aug; 271(32):19585-91. PubMed ID: 8702653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms.
    Welch PJ; Wang JY
    Mol Cell Biol; 1995 Oct; 15(10):5542-51. PubMed ID: 7565706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
    McWhirter JR; Wang JY
    Mol Cell Biol; 1991 Mar; 11(3):1553-65. PubMed ID: 1705008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle.
    Welch PJ; Wang JY
    Cell; 1993 Nov; 75(4):779-90. PubMed ID: 8242749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
    Allen PB; Morgan GJ; Wiedemann LM
    Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
    Hantschel O; Superti-Furga G
    Nat Rev Mol Cell Biol; 2004 Jan; 5(1):33-44. PubMed ID: 14708008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.
    Cicchetti P; Mayer BJ; Thiel G; Baltimore D
    Science; 1992 Aug; 257(5071):803-6. PubMed ID: 1379745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
    Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
    Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
    Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
    Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
    Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
    Okuda K; D'Andrea A; Etten RA; Griffin JD
    J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
    Jung JH; Pendergast AM; Zipfel PA; Traugh JA
    Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.
    Kipreos ET; Wang JY
    Science; 1992 Apr; 256(5055):382-5. PubMed ID: 1566087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Bcr serine kinase by tyrosine phosphorylation.
    Liu J; Wu Y; Ma GZ; Lu D; Haataja L; Heisterkamp N; Groffen J; Arlinghaus RB
    Mol Cell Biol; 1996 Mar; 16(3):998-1005. PubMed ID: 8622703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
    Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
    Liu J; Wu Y; Arlinghaus RB
    Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
    Lugo TG; Pendergast AM; Muller AJ; Witte ON
    Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.